CY1119149T1 - Αντικαρκινικη πρωτεϊνη συντηξης - Google Patents
Αντικαρκινικη πρωτεϊνη συντηξηςInfo
- Publication number
- CY1119149T1 CY1119149T1 CY20171100632T CY171100632T CY1119149T1 CY 1119149 T1 CY1119149 T1 CY 1119149T1 CY 20171100632 T CY20171100632 T CY 20171100632T CY 171100632 T CY171100632 T CY 171100632T CY 1119149 T1 CY1119149 T1 CY 1119149T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fusion protein
- domain
- sequence
- terminus
- cancer fusion
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Μια πρωτεΐνη σύντηξης που περιλαμβάνει την επικράτεια (α) η οποία είναι ένα λειτουργικό θραύσμα της αλληλουχίας πρωτεΐνης hTRAIL, το οποίο θραύσμα αρχίζει με ένα αμινοξύ σε μια θέση όχι χαμηλότερα από την hTRAIL95 ή ένα ομόλογο του εν λόγω λειτουργικού θραύσματος που έχει τουλάχιστον 70% ταυτότητα αλληλουχίας· και την επικράτεια (β) η οποία είναι μια αλληλουχία αντιαγγειογενετικού πεπτιδίου τελεστή, όπου η αλληλουχία της επικράτειας (β) συνδέεται στο C-τελικό ή στο Ν-τελικό άκρο της επικράτειας (α). Η πρωτεΐνη σύντηξης μπορεί να χρησιμοποιηθεί για τη θεραπεία καρκινικών ασθενειών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL393578A PL219845B1 (pl) | 2011-01-05 | 2011-01-05 | Przeciwnowotworowe białko fuzyjne |
PCT/EP2012/050145 WO2012093158A1 (en) | 2011-01-05 | 2012-01-05 | Anticancer fusion protein |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119149T1 true CY1119149T1 (el) | 2018-02-14 |
Family
ID=45476512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100632T CY1119149T1 (el) | 2011-01-05 | 2017-06-15 | Αντικαρκινικη πρωτεϊνη συντηξης |
Country Status (25)
Country | Link |
---|---|
US (1) | US9175059B2 (el) |
EP (1) | EP2661496B1 (el) |
JP (1) | JP5797773B2 (el) |
KR (1) | KR101950043B1 (el) |
CN (1) | CN103228788B (el) |
AU (1) | AU2012204900B2 (el) |
BR (1) | BR112013016980B1 (el) |
CA (1) | CA2814597C (el) |
CY (1) | CY1119149T1 (el) |
DK (1) | DK2661496T3 (el) |
EA (1) | EA025830B1 (el) |
ES (1) | ES2628377T3 (el) |
HR (1) | HRP20170905T1 (el) |
HU (1) | HUE032576T2 (el) |
IL (1) | IL226205B (el) |
LT (1) | LT2661496T (el) |
ME (1) | ME02756B (el) |
MX (1) | MX339203B (el) |
PL (2) | PL219845B1 (el) |
PT (1) | PT2661496T (el) |
RS (1) | RS56095B1 (el) |
SG (1) | SG190049A1 (el) |
SI (1) | SI2661496T1 (el) |
UA (1) | UA108778C2 (el) |
WO (1) | WO2012093158A1 (el) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970478B1 (en) | 2013-03-12 | 2020-05-06 | Molecular Templates, Inc. | Cd20-binding immunotoxins for inducing cellular internalization and methods using same |
WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
US10875903B2 (en) | 2013-05-06 | 2020-12-29 | China Pharmaceutical University | Bifunctional fusion proteins to inhibit angiogenesis in tumor microenvironment and to activate adaptive immune responses and the genes and uses thereof |
WO2015191764A1 (en) | 2014-06-11 | 2015-12-17 | Molecular Templates, Inc. | Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same |
WO2015113005A1 (en) | 2014-01-27 | 2015-07-30 | Molecular Templates, Inc. | Mhc class i epitope delivering polypeptides |
EP3102245B1 (en) | 2014-02-05 | 2021-09-08 | Molecular Templates, Inc. | Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
CN108064247B (zh) | 2015-02-05 | 2022-06-03 | 分子模板公司 | 包含志贺毒素a亚基效应物区域的多价cd20结合分子及其富集组合物 |
US10428132B2 (en) | 2015-02-11 | 2019-10-01 | West China Hospital, Sichuan University | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof |
EP3303373B1 (en) | 2015-05-30 | 2020-04-08 | Molecular Templates, Inc. | De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same |
US20210008208A1 (en) | 2016-12-07 | 2021-01-14 | Molecular Templates, Inc. | Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation |
US20200024312A1 (en) | 2017-01-25 | 2020-01-23 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes |
CA3097178A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69328091T2 (de) | 1992-04-29 | 2000-10-12 | Georgetown University, Washington | Bindungspeptide zur interaktion mit wachstumsfaktoren als liganden des rezeptors des epidermiswachstumsfactor und des erbb-2-rezeptor |
IL149261A0 (en) | 1995-06-29 | 2002-11-10 | Immunex Corp | Antibodies that bind a tnf related apoptosis inducing ligand (trail) peptide |
JPH11513249A (ja) * | 1995-09-27 | 1999-11-16 | メディカル・リサーチ・カウンシル | プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
DE10247755B4 (de) * | 2002-10-14 | 2006-01-19 | Pfizenmaier, Klaus, Prof. Dr. | Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine |
CN1257187C (zh) | 2003-10-22 | 2006-05-24 | 上海恰尔生物技术有限公司 | 钙网蛋白-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 |
US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
ATE501256T1 (de) | 2003-11-03 | 2011-03-15 | Beijing Sunbio Biotech Co Ltd | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung |
CN1256347C (zh) * | 2003-12-10 | 2006-05-17 | 中国人民解放军第二军医大学 | 激肽原第五结构域-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途 |
WO2007022157A2 (en) | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues |
WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
GB0723059D0 (en) | 2007-11-23 | 2008-01-02 | Nat Univ Ireland | Improved cytokine design |
GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
CL2009001191A1 (es) | 2008-05-14 | 2010-07-02 | Genentech Inc | Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin. |
CN102137869B (zh) | 2008-06-30 | 2018-07-06 | 宾夕法尼亚大学 | Fn14/TRAIL融合蛋白 |
PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
CA2814595C (en) * | 2010-12-03 | 2020-06-16 | Adamed Sp. Z O.O. | Anticancer fusion protein |
-
2011
- 2011-01-05 PL PL393578A patent/PL219845B1/pl unknown
-
2012
- 2012-01-05 KR KR1020137020558A patent/KR101950043B1/ko active IP Right Grant
- 2012-01-05 BR BR112013016980-0A patent/BR112013016980B1/pt active IP Right Grant
- 2012-01-05 ME MEP-2017-131A patent/ME02756B/me unknown
- 2012-01-05 CN CN201280003863.3A patent/CN103228788B/zh active Active
- 2012-01-05 CA CA2814597A patent/CA2814597C/en active Active
- 2012-01-05 EP EP12700215.2A patent/EP2661496B1/en active Active
- 2012-01-05 JP JP2013547859A patent/JP5797773B2/ja active Active
- 2012-01-05 RS RS20170597A patent/RS56095B1/sr unknown
- 2012-01-05 WO PCT/EP2012/050145 patent/WO2012093158A1/en active Application Filing
- 2012-01-05 EA EA201391005A patent/EA025830B1/ru unknown
- 2012-01-05 LT LTEP12700215.2T patent/LT2661496T/lt unknown
- 2012-01-05 MX MX2013007872A patent/MX339203B/es active IP Right Grant
- 2012-01-05 DK DK12700215.2T patent/DK2661496T3/en active
- 2012-01-05 AU AU2012204900A patent/AU2012204900B2/en active Active
- 2012-01-05 US US13/978,090 patent/US9175059B2/en active Active
- 2012-01-05 PT PT127002152T patent/PT2661496T/pt unknown
- 2012-01-05 SG SG2013032768A patent/SG190049A1/en unknown
- 2012-01-05 ES ES12700215.2T patent/ES2628377T3/es active Active
- 2012-01-05 SI SI201230978T patent/SI2661496T1/sl unknown
- 2012-01-05 HU HUE12700215A patent/HUE032576T2/en unknown
- 2012-01-05 PL PL12700215T patent/PL2661496T3/pl unknown
- 2012-05-01 UA UAA201309548A patent/UA108778C2/ru unknown
-
2013
- 2013-05-07 IL IL226205A patent/IL226205B/en active IP Right Grant
-
2017
- 2017-06-13 HR HRP20170905TT patent/HRP20170905T1/hr unknown
- 2017-06-15 CY CY20171100632T patent/CY1119149T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
CY1120055T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
CY1122079T1 (el) | Πρωτεϊνες επαναληψης διπεπτιδιου ως θεραπευτικος στοχος στις νευροεκφυλιστικες νοσους με επεκταση επαναληψης των εξανουκλεοτιδιων | |
CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
CY1122691T1 (el) | Πρωτεϊνες δεσμευσης αλβουμινης ορου | |
CY1116099T1 (el) | Πρωτεϊνη συντηξης κατα του καρκινου | |
CY1121953T1 (el) | Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων | |
CY1122564T1 (el) | Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ | |
EA201491049A1 (ru) | Противораковый слитый белок | |
CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
CY1124435T1 (el) | Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α | |
CY1119751T1 (el) | Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3 | |
CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
CY1126072T1 (el) | Περιοχες gla ως θεραπευτικοι παραγοντες | |
ES2676023T3 (es) | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso | |
CY1118200T1 (el) | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
ES2676499T3 (es) | Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones | |
CY1119737T1 (el) | Νεες συνθεσεις και μεθοδοι | |
CY1120132T1 (el) | Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους | |
CY1121347T1 (el) | Πρωτεϊνη συντηξης | |
CY1121427T1 (el) | Χρηση ενος μοριου mir172 για τη μειωση της φλεγμονhς |